Headquartered in Hoboken, NJ Fiscal year ends April NYSE: WLY wiley.com
John Wiley & Sons (NYSE: WLY) is a global knowledge company with over 200 years of history in authoritative scientific, technical, medical, and scholarly content and research intelligence. The company operates in two segments: Research and Learning. The Research segment encompasses Research Publishing (approximately 2,500 journals following the Emerald acquisition, open access publishing, and society partnerships) and Research Solutions (AI and data licensing, clinical outcome assessments, advertising services, and publishing services). The Learning segment includes Academic (digital courseware, textbooks, and inclusive access programs for higher education) and Professional (professional development content, certifications, and trade publishing). Wiley is rapidly expanding into AI and data analytics, licensing its proprietary scientific content and databases for model training, commercial applications, and subscription knowledge feeds across verticals including life sciences, healthcare, chemistry, materials science, and financial services. The company serves individual researchers, universities, Fortune 500 R&D teams, government agencies, and AI companies worldwide. Updated
As sticky inflation continues to chip away at fixed incomes, retirees need dividend payers whose business models can absorb price pressure rather than crumble under it. John Wiley & Sons (NYSE:WLY) is…
Alex Sirois The current S&P 500 dividend yield is 1.24%. The highest it’s ever been at the end of a calendar year from 1933 through 2023 was 8.11% in 1941. The highest since 2000…
John Wiley & Sons (NYSE: WLY) is a global knowledge company with over 200 years of history in authoritative scientific, technical, medical, and scholarly content and research intelligence. The company operates in two segments: Research and Learning.
The Wall Street consensus 12-month price target for WLY is $68.00.
